سعر Heparin sodium 5000 i.u./ml 100 s.c. amp. 2026

Heparin sodium 5000 IU/ml subcutaneous injection, 100 ampoules (manufacturer not stated in the source name).

• Prophylaxis and treatment of venous thrombosis and pulmonary embolism.DailyMed (U.S. National Library of Medicine)
• Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and of peripheral arterial embolism.DailyMed (U.S. National Library of Medicine)
• Treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation).DailyMed (U.S. National Library of Medicine)

• History of heparin-induced thrombocytopenia (HIT) or HIT with thrombosis, or thrombocytopenia with pentosan polysulfate.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Known hypersensitivity to heparin or pork products.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Full-dose regimens where suitable blood coagulation tests cannot be performed at appropriate intervals; uncontrollable bleeding state (except when due to DIC).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Fatal medication errors: confirm the correct strength and vial/ampoule before administration; do not confuse with catheter lock flush products.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hemorrhage, including fatal events, can occur at virtually any site; use with caution in conditions with increased bleeding risk (e.g. bacterial endocarditis, severe hypertension, spinal/major surgery, haemophilia, GI ulceration).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Heparin-induced thrombocytopenia (HIT) and HIT with thrombosis may occur, including up to several weeks after stopping; discontinue if platelets fall below 100,000/mm3 or recurrent thrombosis develops.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Oral anticoagulants (warfarin, dicumarol)Heparin may prolong the one-stage prothrombin time; draw INR samples at least 5 hours after the last IV dose or 24 hours after the last subcutaneous dose.DailyMed (U.S. National Library of Medicine)
• Platelet inhibitors (NSAIDs, dipyridamole, thienopyridines, GP IIb/IIIa antagonists, dextran)May induce bleeding; use with caution.DailyMed (U.S. National Library of Medicine)
• Andexanet alfaUnresponsiveness to unfractionated heparin with serious thrombotic events; avoid heparin after andexanet alfa.DailyMed (U.S. National Library of Medicine)

• No available data in pregnant women to inform a drug-associated risk; published reports did not show increased adverse maternal or fetal outcomes. Animal studies showed early embryo-fetal death but no teratogenicity at about 10 times the maximum recommended human dose.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• No information on presence in human milk; because of its large molecular weight heparin is unlikely to be excreted in milk or absorbed orally by the infant. Benzyl alcohol (in preserved formulations) may reach milk; a preservative-free formulation is recommended.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Heparin sodium: Binds antithrombin III and markedly enhances its inhibition of activated clotting factors, particularly factor Xa and thrombin (IIa); does not lyse existing clots.